MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
Metrics: PDF 1603 views | HTML 2285 views | ?
Kei Kawaguchi1,2,3, Kentaro Igarashi1,2, Takashi Murakami1,2, Tasuku Kiyuna1,2, Thinzar M. Lwin2, Ho Kyoung Hwang1,2, Jonathan C. Delong2, Bryan M. Clary2, Michael Bouvet2, Michiaki Unno3 and Robert M. Hoffman1,2
1AntiCancer, Inc., San Diego, CA, USA
2Department of Surgery, University of California, San Diego, CA, USA
3Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan
Robert M. Hoffman, email: all @anticancer.com
Michael Bouvet, email: firstname.lastname@example.org
Bryan M. Clary, email: email@example.com
Keywords: pancreatic cancer, PDOX, nude mice, orthotopic, drug-response
Received: April 15, 2017 Accepted: April 20, 2017 Published: May 07, 2017
A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown orthotopically in the pancreatic tail of nude mice to establish a patient-derived orthotopic (PDOX) model. Seven weeks after implantation, PDOX nude mice were divided into the following groups: untreated control (n = 7); gemcitabine (100 mg/kg, i.p., once a week for 2 weeks, n = 7); cobimetinib (5 mg/kg, p.o., 14 consecutive days, n = 7); trametinib (0.3 mg/kg, p.o., 14 consecutive days, n = 7); trabectedin (0.15 mg/kg, i.v., once a week for 2 weeks, n = 7); temozolomide (25 mg/kg, p.o., 14 consecutive days, n = 7); carfilzomib (2 mg/kg, i.v., twice a week for 2 weeks, n = 7); bortezomib (1 mg/kg, i.v., twice a week for 2 weeks, n = 7); MK-1775 (20 mg/kg, p.o., 14 consecutive days, n = 7); BEZ-235 (45 mg/kg, p.o., 14 consecutive days, n = 7); vorinostat (50 mg/kg, i.p., 14 consecutive days, n = 7). Only the MEK inhibitors, cobimetinib and trametinib, regressed tumor growth, and they were more significantly effective than other therapies (p < 0.0001, respectively), thereby demonstrating the precision of the PDOX models of PDAC and its potential for individualizing pancreatic-cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.